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Rituximab is becoming the preferred second-line choice for
steroid-refractory warm autoimmune hemolytic anemia (wAIHA)
and the first-line choice for cold agglutinin disease (CAD). However,
rituximab is an expensive treatment that is not available world-
wide; it is also not in indication or reimbursable in all countries. It
is usually administered at 375 mg/m2 once weekly for 4 weeks,
with high efficacy (overall response rate [ORR] .80%) in wAIHA,
both idiopathic and secondary forms.1-5 At variance, cold forms
exhibit lower response rates (40%-50%, mainly partial) when
rituximab is used as a single agent; therefore, combination treat-
ments with purine analogues (eg, fludarabine, bendamustine) have
been proposed with better ORRs, although with side effects.6
Even if rituximab has a good safety profile, infusion reactions,
immunosuppression, and hepatitis virus/mycobacterial reac-
tivations can occur. To minimize side effects and reduce costs,
and considering the lower lymphocyte burden in autoimmune
hematologic conditions compared with lymphoproliferative
diseases, low-dose (LD) rituximab (100mg fixed dose onceweekly
for 4 weeks) has been used in several autoimmune diseases, in-
cluding immune thrombocytopenic purpura and AIHA.7-10
Ten years ago, we prospectively assessed the efficacy of LD ritux-
imab in primary wAIHA and CAD in a pilot study (#NCT01345708);
we reported;80% response rates in wAIHA and;60% in CAD,
along with a ;50% reduction in steroid administration.10 Here,
we continued to prospectively evaluate 20 of the original pa-
tients and included an additional 34 consecutive patients from
June 2012 until April 2018, according to the original protocol
(100 mg fixed dose once weekly for 4 weeks combined with a
short course of prednisone, starting at 1 mg/kg per day with
subsequent tapering and discontinuation within 3 months). As
shown in Table 1, wAIHA cases accounted for one-half of the
patients, followed by CAD, mixed, and atypical cases. All patients
enrolled had hemoglobin levels ,10 g/dL or lactate dehydro-
genase levels .1.5 3 the upper limit of normal, and the great
majority had received at least 1 course of steroids. The time
from diagnosis of AIHA to initiation of rituximab therapy was
$12 months in 15 cases (3 of whom had received cytotoxic im-
mune suppressors and exhibited slightly reduced immunoglob-
ulin levels at baseline). Patients were followed up for a median of
53 months (range, 6-120 months), and ORR was invariably.80%
within the first 3 years; complete response (CR) rates increased
from 46% at month 12 to .60% at month 16 and thereafter.
Because recent evidence pinpoints hemoglobin levels at onset and
AIHA type as predictors of relapse/refractoriness to therapy,11,12
we investigated the efficacy of LD rituximab in the various AIHA
forms, divided into wAIHA, CAD, mixed (direct antiglobulin test
result positive for immunoglobulin G [IgG] plus high-titer C), and
atypical ones (negative direct antiglobulin test result). Response
rates were better in wAIHA compared with other forms (CAD,
Table 1. Clinical and laboratory characteristics of patients
with AIHA at enrollment and treatment outcome
Characteristic Patients (N 5 54)
Age, median (range), y 66 (20-90)
Sex, n (%)
Female 32 (59)
Male 22 (41)
AIHA type, n (%)
wAIHA IgG 23 (42.6)
wAIHA IgG1C 4 (7.4)
Cold 20 (37)
Mixed 4 (7.4)
Atypical 3 (5.6)
Hemoglobin, median (range), g/dL 9.6 (4.4-13.2)
LDH 3 ULN, median (range) 1.36 (0.5-4.5)
Unconjugated bilirubin, median (range), mg/dL 1.72 (0.4-9.7)
Reticulocytes, median (range), 3109/L 145 (27-550)
IgA, median (range), g/L 137 (42-385)
IgG, median (range), g/L 681 (401-1014)
IgM, median (range), g/L 110 (32-303)
Time to LD rituximab, median (range), mo 7 (0-89)
Prospective follow-up, median (range), mo 53 (6-120)
Month 12 ORR/CR, n (%) 46 (85)/25 (46)
Month 16 ORR/CR, n (%) 35 (83)/26 (62)
Month 112 ORR/CR, n (%) 30 (88)/23 (68)
Month 118 ORR/CR, n (%) 20 (91)/15 (68)
Month 124 ORR/CR, n (%) 18 (95)/15 (79)
Month 136 ORR/CR, n (%) 8 (89)/6 (67)
Duration of response, median (range), mo 15 (3-85)
RFS, median (range), mo 41.9 (14.3-69.5)
Relapsed, n (%) 28 (62)
wAIHA direct antiglobulin test result positive for IgG only (wAIHA IgG) and wAIHA direct
antiglobulin test result positive for IgG and low-titer C (wAIHA IgG1C) types included
14 cases from the pilot study and an additional 13 cases; CAD included 9 and 11 patients,
respectively. Four mixed and 7 atypical AIHA cases were all newly treated in this study.
LDH, lactate dehydrogenase; ULN, upper limit of normal.
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mixed, and atypical; P 5 .05). In particular, in the former, ORR
was .90% at each time point (Figure 1A), and CR rates ranged
from 59% (month 12) to 100% (month 124). This amelioration
of CR over time is in line with the immune-modulating effect
of rituximab that may emerge beyond the well-known B-cell–
depleting activity, as already shown on cytokine levels in the
pilot study.10 Moreover, the progressive increase in response
rates further suggests that rituximab takes a while to work, al-
though the number of evaluable patients decreases over time.
No relationship was found among response rates and baseline
hematologic parameters, or with the time from diagnosis to
initiation of rituximab. Response rates were comparable con-
sidering patients enrolled in the pilot study and the new pa-
tients. We observed no grade 3 or 4 adverse events, and IgA, IgG,
and IgM serum levels at month 112 were comparable to base-
line (mean values of 167 6 133 mg/dL, 758 6 385 mg/dL, and
153 6 162 mg/dL, respectively). Median duration of response was
1 year and 3 months, and 62% of patients relapsed. Relapsed
patients received various treatments, including steroids (n5 15),
cytotoxic immune suppressors (3 azathioprine, 2 cyclophos-
phamide), splenectomy (5), bortezomib (3), and rituximab at
standard doses (3); 14 cases were retreated with LD rituximab, of
whom 9 (64%) with further response. Relapse-free survival
(RFS) significantly correlated with AIHA type: it was longer in
wAIHA (both IgG and IgG1low-titer C) compared with other
cases (64 months [95% CI, 26.6-102] vs 25 months [95% CI, 9.4-
41.6]; P 5 .004]) and was particularly short in mixed and atypical
cases (Figure 1B). Notably, the depth of response at 1 year was
also related to longer RFS, and hemoglobin levels at 12 months
positively correlated with duration of response (r 5 0.37;
P 5 .02). In multivariable analysis according to Cox regression
models, the presence of wAIHA emerged as the only significant
predictor of longer RFS (P 5 .01). Concerning long-term out-
comes, 25 cases reached the 5-year follow-up, and 5 of them
(20.5%) are long-term responders after the first LD rituximab
course.
The analysis of these 10 years of prospective data confirms the
efficacy of LD rituximab in primary AIHA, both as a short-term
response as well as a long-term outcome. Most cases responded
within the first 2 months, and rituximab’s immune-modulating
activity continued in responders, with further amelioration of the
response after month 6.We clearly showed that LD rituximab has
better efficacy and induces sustained responses in warm cases
compared with CAD; this finding supports the hypothesis that
patients with CAD would benefit from a higher rituximab dose
because of a greater burden of clonal autoreactive B cells.6
Moreover, the depth of response correlated with longer re-
sponse duration, similar to what has been observed in onco-
hematologic diseases. In terms of safety, we confirmed that LD
rituximab is safe and tolerable, with no significant changes in
baseline immunoglobulin levels in the 1 year since treatment; LD
rituximab can also be safely re-administered, with an efficacy
in up to 60% of cases and with a cumulative dose lower than that
reached with 1 course at standard doses. These findings suggest
that retreatment with LD rituximab seems more appropriate to
gain a fine-tuning of the autoimmune reactivity, at variance with
the massive B-cell depletion obtained with standard doses. Our
study was not designed to compare low vs standard rituximab
doses in terms of efficacy, safety, and immune reconstitution,
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Figure 1. Response rate and RFS according to AIHA type. (A) Response rates in wAIHA and in all other forms (time cutoff, month136). (B) RFS according to Cox regression
model (timeline cutoff, month160; n5 25). NR, no response; PR, partial response; wAIHA IgG, wAIHA direct antiglobulin test result positive for IgG only; wAIHA IgG1C, wAIHA
direct antiglobulin test result positive for IgG and low-titer C.
LETTERS TO BLOOD blood® 28 FEBRUARY 2019 | VOLUME 133, NUMBER 9 997
D
ow
nloaded from
 https://ashpublications.org/blood/article-pdf/133/9/996/1558154/blood885228.pdf by guest on 09 Septem
ber 2020
however, and an ad hoc study would be advisable to address
these issues. Regarding response rates, our data compare well
with those reported in several studies and meta-analysis for
standard doses.1,2,4,12,13 Likewise, RFS seems comparable be-
tween the 2 schedules, with 20.5% long-term responders at
5 years in the present cohort and 20% in a retrospective multi-
centric study.12 Finally, a lower dose (about one-seventh of the
standard dose) may help in reducing costs for the health services.
Altogether, our data advise the use of LD rituximab as early
second-line treatment in wAIHA, particularly in the presence
of reactivation of hemolysis during initial steroid tapering, in
patients at risk for steroidal side effects or in frail/elderly cases.14
At variance, this schedule seems less effective in cold, mixed,
and atypical cases, suggesting the use of standard doses in these
settings.
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